B
CRL icon

Bellecapital’s Charles River Laboratories CRL Stock Holding History

Bellecapital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24,237
Closed -$4.89M – 172
2023
Q1 		$4.89M Buy
24,237
+673
+3% +$153K 1.22% 26
2022
Q4 		$5.13M Buy
23,564
+666
+3% +$145K 1.44% 23
2022
Q3 		$4.51M Buy
22,898
+6,470
+39% +$1.4M 1.38% 22
2022
Q2 		$3.52M Buy
16,428
+15,035
+1,079% +$3.67M 0.98% 31
2022
Q1 		$396K Sell
1,393
-24
-2% -$7.4K 0.13% 131
2021
Q4 		$534K Sell
1,417
-42
-3% -$16.3K 0.15% 110
2021
Q3 		$602K Buy
1,459
+19
+1% +$7.89K 0.18% 98
2021
Q2 		$533K Buy
1,440
+39
+3% +$13K 0.16% 110
2021
Q1 		$406K Buy
+1,401
New +$389K 0.13% 129

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Bellecapital's CRL Position: Q2 2023 in Review

Bellecapital sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 24,237 shares — an estimated $4.89M sold.

Bellecapital first reported a position in CRL in Q1 2021 and held it in 9 quarters. The position peaked at $5.13M in Q4 2022. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Bellecapital reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • Bellecapital sold 24,237 Charles River Laboratories shares in Q2 2023, an estimated $4.89M.
  • Bellecapital first reported a position in Charles River Laboratories in Q1 2021 and held it in 9 quarters.
  • Bellecapital's Charles River Laboratories position peaked at $5.13M in Q4 2022.
  • 611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Bellecapital's 13F filing for Q2 2023, filed 7 Jul 2023.